Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now?

Impact · against what's priced in

The news for Teva is positive but largely reflects a turnaround that the market has already begun to reward, given the stock's 34% year-to-date gain. The growth in branded sales and margin expansion validate the pivot away from generics, though the slight revenue dip shows the transition is still in progress.

TEVA+0.40

No priced-in read yet